Some of the regulators affected by this treatment however could be implicated in anti-tumorigenic activities (i.e., IL-6 (Jiang et al., 2011)), yet modulation identified in other regulators are potentially implicated in prostate cancer tumorigenesis, such as BHLHE40 (Dmitriev et al., 2015), and SRF (Prencipe et al., 2018). This evidence concerns the gene IL6 and prostate carcinoma.